What Does Global Health Justice Look Like With a Seven-Figure Drug?
By Kevin Doxzen and Diana M. Bowman,
Slate
| 09. 22. 2021
Over the past decade, our ability to alter the human genome has rapidly improved, largely due to advancements in genome editing technologies like CRISPR. Scientists are vigorously pursuing the ultimate goal of making any change to any DNA sequence in any cell of the body. The versatility of these tools has opened the door to treating a range of debilitating diseases, from prevalent neurological conditions to rare forms of cancer. Yet, alongside promising therapeutic applications, we should be worried about the potential unethical and inequitable uses of these technologies.
Universal concern over the potential use and misuse of genome editing reached a peak in 2018 following the surprise announcement of the first edited babies. He Jiankui, a professor overseeing a university lab in China, publicly disclosed his efforts to engineer HIV immunity into human embryos. The international scientific community decried He’s experiment, and the Chinese government eventually filed criminal charges against this rising young scientist. He Jiankui is currently serving a three-year prison term after a Chinese court found him guilty of “illegal medical practice”.
Criticized as...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...